Picture [iito] Life Science Business Portals Media Data 2022 2 650x100px
Financing › Details

Pantherna Therapeutics–SEVERAL: investment, 202201 follow-on financing round €4m led by existing investors Detlev Riesner + HTGF


Period Period 2022-01-11
Organisations Money taker Pantherna Therapeutics GmbH
  Money source SEVERAL
Products Product PAN004 (Pantherna Therapeutics)
  Product 2 venture capital
Index term Index term Acute Respiratory Distress Syndrome (ARDS)
Persons Person Riesner, Detlev (Evotec Biosystems 199906 Scientific Advisory Board + Qiagen Co-Founder)
  Person 2 Caßing, Anke (High-Tech Gründerfonds 202001)

Pantherna Therapeutics GmbH. (1/11/22). "Press Release: Pantherna Therapeutics Secures EUR 4.0 Mio. Follow-on Financing to Advance Its Therapeutic mRNA Development Programs". Hennigsdorf.

Pantherna Therapeutics today announces the successful completion of a follow-on financing round totaling EUR 4.0 Mio. led by existing investors Riesner Verwaltungs GmbH and High-Tech Gründerfonds. The proceeds of this round will be used to accelerate preclinical development activities for its lead program PAN004, an mRNA-based therapeutic for Acute Respiratory Distress Syndrome (ARDS).

ARDS causes a life-threatening damage to the lungs induced by an excessive hyperinflammatory reaction of the lung tissue in response to bacterial and viral infections including SARS-CoV2 (COVID-19). No targeted therapy is available for this syndrome to prevent fluid retention and tissue damage to the lungs. Pantherna Therapeutics is developing a targeted therapy with a new mode of action by expressing a TIE-2 receptor agonist to restore endothelial barrier function.

“The new funds will be used to expand the PAN004 development activities and will also support Pantherna ´s efforts to strengthen its R&D team and activities for advancing its mRNA therapeutics technology for new indications”, comments Dr. Jörg Kaufmann, CSO at Pantherna Therapeutics.

Prof. Detlev Riesner, Qiagen-co-founder and private investor of several Biotech companies, adds: “Qiagen developed the purification of RNA nearly 40 years ago, and in recent years the outstanding impact of mRNA-technology for vaccination became obvious. I am more than happy to follow now the development of mRNA-technology to the urgent need of targeted therapy.”

Dr. Anke Caßing, Principal at High-Tech Gründerfonds, adds: “We are delighted to assist in the new funding round to bring Pantherna ´s innovation a huge step closer to the clinic.”

About Pantherna

Pantherna Therapeutics is a privately-held biopharmaceutical Company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium. Pantherna is based in Hennigsdorf (Brandenburg) close to Berlin, Germany.


Pantherna Therapeutics GmbH
Dr. Gerrit Maass
Neuendorfstrasse 20b
16761 Hennigsdorf
T: +49 3302 2022 400

About High-Tech Gründerfonds

High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 650 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected more than EUR 3.5 billion into the HTGF portfolio via more than 1,800 follow-on financing rounds. HTGF has also successfully sold interests in more than 150 companies.

Investors in this public-private partnership include the Federal Ministry for Economic Affairs and Climate Action, KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Bank, Deutsche Post DHL, Dräger, 1+1 AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.


High-Tech Gründerfonds Management GmbH
Dr. Anke Caßing, Principal
Schlegelstraße 2
53113 Bonn
T: +49 228 82300 148

Record changed: 2022-04-12


Picture [iito] [LSE] Business Portal 650x200px

More documents for Pantherna Therapeutics GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [iito] [LSE] Business Portal 650x300px

» top